UniQure Reports Gene Therapy Slows Huntington’s Disease Progression Over Four Years

UniQure has reported that its gene therapy for Huntington’s disease continues to slow the disease’s progress four years after it was implanted into patients’ brains. The Dutch biotech company announced the results Tuesday, but the data comes with a note of caution: the treatment’s benefit has shrunk compared to a similar analysis done one year ago, just as the Food and Drug Administration begins reviewing the company’s marketing application.

The therapy, called AMT-130, is a one-time surgical implant designed to treat the neurodegenerative disease. In the latest analysis, patients who received a high dose of the therapy showed a 44% slower rate of disease progression compared to matched participants in an external control group drawn from a large natural history study. That gap was not statistically significant.

What the Trial Actually Measures

The design of the study matters here. UniQure is comparing its patients to a control group built from existing data, not to a separate group of people receiving a placebo. That means the comparison group did not receive the therapy at all — they simply lived out the course of the disease as scientists had previously recorded it.

The 44% figure describes how much slower the treated group moved through the disease relative to that historical record. Whether that difference holds up against a placebo-controlled trial remains an open question.

The lack of statistical significance is notable. A statistically significant result would suggest the observed effect is unlikely to be due to chance. Here, the company has not reached that threshold.

The FDA Review Timeline

The timing of this update matters. The FDA is currently reviewing UniQure’s marketing application for AMT-130.

The one-year comparison shows the treatment’s benefit has waned. That raises questions about whether the effect will continue to hold over time. For a disease like Huntington’s, where progression is relentless, even a slowing of disease is meaningful.

“The difference was not statistically significant.”

That sentence captures the core tension in the announcement. The therapy appears to be doing something — the 44% figure suggests as much — but the data as presented does not meet the formal standard of statistical proof.

What This Means for Patients

Four years of slowing disease progression is a promising trend. But the lack of statistical significance means the evidence is not yet strong enough to guarantee the effect will hold up in larger trials.

The company has not announced when it expects to complete the FDA review process. What is clear is that the agency’s decision will hinge on a full assessment of all available data, including the durability of the effect over time.

Key Facts From the Announcement

• Trial: A one-time surgical implant of AMT-130
• Disease: Huntington’s disease, a neurodegenerative disorder
• Comparison group: Matched participants in an external control group based on a large natural history study
• One-year comparison: The treatment’s benefit has waned compared to a similar analysis conducted one year ago
• FDA: Currently reviewing UniQure’s marketing application
• 44% figure: Slower rate of disease progression in treated patients, not statistically significant

The announcement is a reminder that clinical development is rarely neat. A drug can show promise, then require years of observation to determine whether that promise holds. UniQure’s therapy has slowed disease progression for four years — but the data has not yet reached the threshold of statistical proof.

Whether the FDA will find that progress sufficient remains to be seen. The agency’s review will consider all available data, including the durability of the effect over time. For now, the company has reported a trend — and the industry waits to see if that trend becomes a rule.

See the a run of 39 images at STAT.

clinical trial · FDA · gene therapy · Huntington's disease · UniQure